RecruitingPhase 4NCT04221997

Trial With the Treatment of Sertraline in Youth With Generalized, Separation and/or Social Anxiety Disorders.

Extracellular Vesicles as Predictors of Antidepressant Outcomes in Pediatric Anxiety (EV-SOPRANO)

Sponsor

University of Cincinnati

Enrollment

150 participants

Start Date

Nov 1, 2019

Study Type

INTERVENTIONAL

Conditions

Anxiety Disorders

Summary

A Multicenter, acute, randomized, double-blind, placebo-controlled, flexible-dose trial with the treatment of sertraline.

Eligibility

Min Age: 8 YearsMax Age: 17 Years

Inclusion Criteria26

Written, informed assent and consent.
Patients, parent/guardian/LAR must be fluent in the English.
years of age, inclusive, at Visit 1, and who have a parent/guardian/LAR.
Patients must meet DSM-5 criteria for generalized, social and/or separation anxiety disorder, confirmed by the MINI-KID with no lifetime history of mania, OCD or significant history of trauma exposure.
PARS score ≥15 at Visits 1 and 2.
Caregiver who is willing to consent to be responsible for safety monitoring of the patient, provide information about the patient's condition, oversee the administration of the investigational product.
No clinically significant abnormalities on physical examination.
Negative pregnancy test at Visit 1 in females.
Sexually active patients must practice a reliable method of contraception (Section 15.0) that will continue for the duration of the study and within 30 days following the end of study participation.
Reliable methods of contraception are defined below; other forms of contraceptives (pharmacological and/or non-pharmacological) are not accepted.
surgical sterilization
oral contraceptives (e.g., estrogen-progestin combination or progestin)
transdermally-delivered contraceptives (e.g., Ortho-Evra), depot injections (e.g.,
Depo-Provera)
vaginal contraceptive ring (e.g., NuvaRing), contraceptive implants (e.g., Implanon, Norplant
II/Jadelle)
an intrauterine device or
diaphragm plus condom.
Written, informed assent and consent.
Patients, parent/guardian/LAR must be fluent in the English.
to 17 years of age, inclusive, at Visit 1, and who have a parent/guardian/LAR.
No history of any DSM-5 disorders (nicotine use disorder is permitted, history of adjustment disorder is permitted), confirmed by the MINI-KID.
Caregiver who is willing to consent to be responsible for safety monitoring of the patient, provide information about the patient.
No clinically significant abnormalities on physical examination. Negative pregnancy test at Screening in females.
Negative urine drug screen at Screening.
No first-degree relatives with an affective, anxiety or psychotic disorder.

Exclusion Criteria12

Subjects Co-occurring DSM-5 diagnosis mood (except persistent depressive disorder, unspecified depressive disorder or co- occurring anxiety disorders, provided that the primary diagnosis is generalized, social and/or separation anxiety disorder(s)), eating, bipolar, or psychotic disorders.
A history of treatment with SSRIs within 12 weeks of Visit 2 (Baseline) or current pharmacotherapy with CNS effects that require \>5 half-lives for discontinuation.
A history of major neurological or medical illness or head trauma with loss of consciousness for ≥5 minutes.
Lifetime history of mania, OCD, or significant history of trauma exposure.
History of hypersensitivity to sertraline.
Lifetime diagnosis of intellectual disability or history of IQ \<70.
History of alcohol/substance use disorder or any substance abuse within the past 6 months (nicotine dependence is permitted).
Current psychotherapy stable for \<2 months prior to Visit 2 (Baseline).
Females will not be eligible to participate if they are pregnant, breast feeding or lactating.
The subject lives \>100 miles from the University of Cincinnati or \>90 minutes from the CU site or is not able to attend the follow-up visits.
Patients who are unable to swallow capsules.
Is currently considered at risk of suicide in the opinion of the investigator, represents an inappropriate risk to the participant and/or could confound the interpretation of the study results.

Interventions

DRUGsertraline

Sertraline is an antidepressant in a group of drugs called selective serotonin reuptake inhibitors (SSRIs)

Locations(1)

University of Cincinnati

Cincinnati, Ohio, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04221997

Related Trials

Study of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders

NCT000180571 location

Development of Magnetic Resonance Imaging Techniques for Studying Mood and Anxiety Disorders

NCT003971111 location